Frequently Asked Questions

Investor FAQs

Where is the Company located?
Our corporate office is located in Novato, California. 
 
1537 South Novato Blvd., #5 
Novato, CA  94947 
 
Mailing Address:
Mosaic ImmunoEngineering Inc. 
19881 Brookhurst Street, C-245 
Huntington Beach, CA 92646 
When was the Company founded?
The Company was founded on March 24, 1992 under its former name, Patriot Scientific Corporation, a Delaware corporation. On August 21, 2020, Patriot Scientific Corporation was merged with Mosaic ImmunoEngineering Inc., a private biotechnology company.  This merger was effected for the purpose of shifting the strategic priorities of the merged companies toward focusing on the development of immunotherapies to treat and prevent cancer and infectious diseases. The Company changed its name from Patriot Scientific Corporation to Mosaic ImmunoEngineering, Inc. on November 30, 2020. 
What are the effects of the Company’s name change? 
The name change from Patriot Scientific Corporation to Mosaic ImmunoEngineering Inc. affects all holders of the former Company’s common stock, Series A Convertible Voting Preferred, and Series B Convertible Voting Preferred uniformly. The name change is not intended to, and does not, affect any stockholder’s percentage ownership interest in the Company. The name change does not change the terms of any class of our capital stock. Following the name change, the shares of our capital stock retained the same voting rights and are identical in all other respects to our previous capital stock. 
What is the Company’s trading or  ticker symbol? 
On December 31, 2020, our trading symbol changed to "CPMV" on the OTC Markets Pink.  On January 19, 2021, our stock began trading on the OTCQB® Venture Market. The new trading symbol, CPMV, was derived from CowPea Mosaic Virus, which is central to the Company’s core technology platform.  Previously, our common stock was quoted on the OTC Markets Pink tier under the trading symbol "PTSCD.”
What are the effects of the Company’s reverse stock split? 
The Reverse Stock Split reduced the number of fully diluted shares of the Company’s common stock issued and outstanding, including the number of shares issuable upon the conversion of Series A and Series B Convertible Voting Preferred Stock, from approximately 4 billion shares to approximately 8 million shares.  Every 500 outstanding shares of common stock, which were outstanding on the effective date of December 2, 2020, have been combined into and automatically become one (1) outstanding share of common stock of the Company without increasing or decreasing the par value of each share of common stock.  No fractional share shall be issued in connection with the foregoing combination of the shares pursuant to the Reverse Stock Split.  Instead, the Company issued to the Company’s stockholders holding a fractional share of common stock one additional share of common stock for each fractional share.  Each stockholder’s percentage ownership interest in the Company and proportional voting power remains virtually unchanged as a result of the Reverse Stock Split, except for minor changes and adjustments that resulted from rounding fractional shares into whole shares.  
 
In connection with the Reverse Stock Split, the number of authorized shares of common stock was reduced from 600,000,000 shares to 100,000,000 shares. 
Do I need to exchange my paper certificate as a result of the name change and reverse stock split? 
Certificated Shares: 
 
Stockholders holding paper certificates may (but are not required to) send the certificates to the Company’s transfer agent at the address given below. The transfer agent will issue a new share certificate reflecting the Name Change and terms of the Reverse Stock Split to each requesting stockholder.  Exchanging your certificate is not required, and therefore, the cost of issuing the new certificate will be borne by the holder of the certificate.   
Please contact Issuer Direct Corporation for further information, related costs and procedures before sending any paper certificates.  
 
Issuer Direct Corporation 
1981 Murray Holladay Rd., Suite 100 
Salt Lake City, UT  84117 
Tel: +1.801.272.9294 
Fax:+1.801.277.3147 
 
 
Non-Certificated Shares: 
 
Stockholders who are holding their shares in electronic form at a brokerage firm, bank or other nominee will automatically have their positions adjusted to reflect the Reverse Stock Split. 
Who is the Company’s transfer agent? 
The transfer agent for Mosaic ImmunoEngineering Inc. is Issuer Direct Corporation. 
 
Issuer Direct Corporation 
1981 Murray Holladay Rd., Suite 100 
Salt Lake City, UT  84117 
Tel: +1.801.272.9294 
Fax: +1.801.277.3147 
Who are the Company’s independent auditors? 
The Company’s independent auditors are KMJ Corbin & Company LLP. 
 
KMJ Corbin & Company LLP  
18201 Von Karman Ave., Suite 450 
Irvine, CA. 92612 
What is the Company’s CUSIP #?
On December 2, 2020, the CUSIP number of our common stock was changed to 61945M101.   
 
Prior to December 2, 2020, the CUSIP number of our common stock was 70336N107.   
Who is the Company’s legal counsel? 
The Company’s legal counsel is Duane Morris LLP.  
 
Duane Morris LLP  
One Riverfront Plaza 
1037 Raymond Boulevard, Suite 1800 
Newark, NJ 07102-5429 
How can I contact the Company? 
Please refer to our Contact Us page or contact our investor relations directly at 
(657) 208-0890.